Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Sensei Biotherapeutics, Inc. (SNSE) had Income from Continuous Operations of $-21.09M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-21.09M |
|
-- |
|
-- |
|
$22.29M |
|
$-22.29M |
|
$1.20M |
|
$-21.09M |
|
$-21.09M |
|
$-21.09M |
|
|
Income from Continuous Operations |
$-21.09M |
$-21.09M |
|
$-21.09M |
|
$-22.29M |
|
$-22.15M |
|
1.26M |
|
1.26M |
|
$-16.72 |
|
$-16.72 |
|
| Balance Sheet Financials | |
$21.51M |
|
$0.08M |
|
$1.40M |
|
$22.90M |
|
$4.25M |
|
-- |
|
$0.06M |
|
$4.31M |
|
$18.59M |
|
$18.59M |
|
$18.59M |
|
1.26M |
|
| Cash Flow Statement Financials | |
$-20.45M |
|
$19.77M |
|
$-0.65M |
|
$9.99M |
|
$8.67M |
|
$-1.33M |
|
$1.27M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.06 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-20.22M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-113.41% |
|
-113.41% |
|
-92.07% |
|
-113.41% |
|
$14.73 |
|
$-16.03 |
|
$-16.22 |
|